{"id":"temodal","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Acute nephropathy","Anemia","Aplastic anemia","Bone marrow depression","Breastfeeding (mother)","Hepatic failure","Lymphocytopenia","Myelodysplastic syndrome","Neutropenic disorder","Pancytopenia","Pneumocystosis jiroveci pneumonia","Pregnancy, function","Thrombocytopenic disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL810","moleculeType":"Small molecule","molecularWeight":"194.15"},"aliases":["Temozolomide"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-28T06:26:45.600Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T09:50:23.664473+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Astrocytoma, anaplastic","diseaseId":"astrocytoma-anaplastic","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Ewing's sarcoma","diseaseId":"ewing's-sarcoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Glioblastoma multiforme of brain","diseaseId":"glioblastoma-multiforme-of-brain","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Glioma, malignant","diseaseId":"glioma-malignant","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00268385","phase":"PHASE1","title":"Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-12-16","conditions":"Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma","enrollment":83},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT05432804","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-20","conditions":"MGMT-Methylated Glioblastoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma","enrollment":97},{"nctId":"NCT02152982","phase":"PHASE2, PHASE3","title":"Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-15","conditions":"Glioblastoma, Gliosarcoma","enrollment":447},{"nctId":"NCT05691491","phase":"PHASE1, PHASE2","title":"Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-09-28","conditions":"Advanced Malignant Solid Neoplasm, Advanced Microsatellite Stable Colorectal Carcinoma, Hematopoietic and Lymphatic System Neoplasm","enrollment":58},{"nctId":"NCT03581292","phase":"PHASE2","title":"Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-11-06","conditions":"Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma","enrollment":38},{"nctId":"NCT03528642","phase":"PHASE1","title":"Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-01","conditions":"Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3","enrollment":40},{"nctId":"NCT04394858","phase":"PHASE2","title":"Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-17","conditions":"Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma","enrollment":46},{"nctId":"NCT07326566","phase":"PHASE2","title":"Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII","status":"RECRUITING","sponsor":"Black Diamond Therapeutics, Inc.","startDate":"2026-04","conditions":"Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM","enrollment":162},{"nctId":"NCT03197506","phase":"PHASE2","title":"Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-01-15","conditions":"Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma","enrollment":52},{"nctId":"NCT06805305","phase":"PHASE2","title":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","status":"RECRUITING","sponsor":"Diakonos Oncology Corporation","startDate":"2025-03-17","conditions":"Glioblastoma (GBM)","enrollment":180},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT03749187","phase":"PHASE1","title":"BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2019-04-03","conditions":"Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation","enrollment":78},{"nctId":"NCT04919382","phase":"PHASE2","title":"Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Dwight Owen","startDate":"2022-01-26","conditions":"Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma","enrollment":56},{"nctId":"NCT06681220","phase":"PHASE1, PHASE2","title":"Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-02-23","conditions":"Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer","enrollment":166},{"nctId":"NCT06202066","phase":"PHASE2","title":"Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-15","conditions":"Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Malignant Solid Neoplasm","enrollment":60},{"nctId":"NCT04396860","phase":"PHASE2, PHASE3","title":"Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-01","conditions":"Gliosarcoma, MGMT-Unmethylated Glioblastoma","enrollment":159},{"nctId":"NCT07452458","phase":"PHASE3","title":"Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"NRG Oncology","startDate":"2026-06-08","conditions":"Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma","enrollment":398},{"nctId":"NCT05463848","phase":"PHASE2","title":"Surgical Pembro +/- Olaparib w TMZ for rGBM","status":"RECRUITING","sponsor":"L. Nicolas Gonzalez Castro, MD, PhD","startDate":"2022-10-21","conditions":"Glioblastoma, Recurrent Glioblastoma","enrollment":78},{"nctId":"NCT03519412","phase":"PHASE2","title":"Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status","status":"COMPLETED","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2019-01-23","conditions":"Colorectal Neoplasms, Microsatellite Instability","enrollment":107},{"nctId":"NCT06346067","phase":"PHASE3","title":"A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erasca, Inc.","startDate":"2024-04-29","conditions":"Advanced or Metastatic NRAS-mutant Melanoma","enrollment":78},{"nctId":"NCT02455557","phase":"PHASE2","title":"SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2015-05-04","conditions":"Glioblastoma, Gliosarcoma","enrollment":66},{"nctId":"NCT01824875","phase":"PHASE2","title":"Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2013-08-08","conditions":"Gastrinoma, Glucagonoma, Insulinoma","enrollment":144},{"nctId":"NCT01946529","phase":"PHASE2","title":"Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-27","conditions":"Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","enrollment":24},{"nctId":"NCT02942264","phase":"PHASE1, PHASE2","title":"Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-12-14","conditions":"Brain Tumor, Astrocytoma, Astroglioma","enrollment":53},{"nctId":"NCT06475235","phase":"PHASE1","title":"Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-18","conditions":"Lymphoma, Primary Central Nervous System Lymphoma","enrollment":15},{"nctId":"NCT06448286","phase":"PHASE3","title":"PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2026-12-01","conditions":"Glioblastoma","enrollment":60},{"nctId":"NCT06709495","phase":"PHASE1, PHASE2","title":"Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas","status":"RECRUITING","sponsor":"David S Shulman, MD","startDate":"2025-01-27","conditions":"Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor","enrollment":63},{"nctId":"NCT04199026","phase":"NA","title":"Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-25","conditions":"Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma","enrollment":20},{"nctId":"NCT03794349","phase":"PHASE2","title":"Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-07-08","conditions":"High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma","enrollment":94},{"nctId":"NCT05095376","phase":"PHASE3","title":"Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2022-03-28","conditions":"Glioblastoma, Gliosarcoma","enrollment":265},{"nctId":"NCT03830918","phase":"PHASE1, PHASE2","title":"Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-03-06","conditions":"Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":59},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT04901702","phase":"PHASE1, PHASE2","title":"Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-06-09","conditions":"Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma","enrollment":90},{"nctId":"NCT07391215","phase":"PHASE1, PHASE2","title":"5G-PEARL: Paxalisib in Malignant Brain Tumours","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2026-01-19","conditions":"Malignant Primary Gliomas, Glioblastoma Multiforme (GBM)","enrollment":64},{"nctId":"NCT06388733","phase":"PHASE3","title":"A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma","status":"RECRUITING","sponsor":"Ivy Brain Tumor Center","startDate":"2024-06-19","conditions":"Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant","enrollment":450},{"nctId":"NCT05781321","phase":"PHASE2","title":"Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-03-23","conditions":"Glioblastoma","enrollment":170},{"nctId":"NCT05432791","phase":"PHASE2, PHASE3","title":"Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-30","conditions":"Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8","enrollment":73},{"nctId":"NCT07025226","phase":"EARLY_PHASE1","title":"Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-12","conditions":"Glioma","enrollment":10},{"nctId":"NCT04216329","phase":"PHASE1","title":"Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-07","conditions":"Gliosarcoma, Newly Diagnosed, Glioblastoma","enrollment":11},{"nctId":"NCT06630260","phase":"PHASE1, PHASE2","title":"5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2024-11-15","conditions":"Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant","enrollment":182},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT05236036","phase":"PHASE1","title":"Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2022-08-08","conditions":"Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype","enrollment":60},{"nctId":"NCT02179086","phase":"PHASE2","title":"Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2014-12-04","conditions":"Glioblastoma","enrollment":606},{"nctId":"NCT04623931","phase":"PHASE2","title":"Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-01-30","conditions":"Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma","enrollment":40},{"nctId":"NCT05588453","phase":"PHASE1, PHASE2","title":"Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain","status":"RECRUITING","sponsor":"Kari Kendra","startDate":"2023-03-01","conditions":"Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma","enrollment":30},{"nctId":"NCT06861244","phase":"PHASE2","title":"Embryonal Tumor With Multilayered Rosettes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-03-06","conditions":"Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos","enrollment":70},{"nctId":"NCT06630325","phase":"PHASE2","title":"A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-24","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":30},{"nctId":"NCT04200443","phase":"PHASE2","title":"Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-01-14","conditions":"Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8","enrollment":72},{"nctId":"NCT02617745","phase":"PHASE2","title":"Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid","status":"COMPLETED","sponsor":"Centre Henri Becquerel","startDate":"2015-11-30","conditions":"Glioblastoma","enrollment":244},{"nctId":"NCT06625047","phase":"PHASE4","title":"Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2024-10-07","conditions":"Astrocytoma, IDH-Mutant, Glioblastoma, Glioma","enrollment":30},{"nctId":"NCT06991101","phase":"PHASE2","title":"Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2025-12-03","conditions":"Glioblastoma, Brain Cancer, Glioblastoma Multiforme","enrollment":190},{"nctId":"NCT04796012","phase":"PHASE1, PHASE2","title":"VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-04-18","conditions":"Solid Tumor, Rhabdomyosarcoma","enrollment":23},{"nctId":"NCT00539591","phase":"PHASE2","title":"Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2008-05-09","conditions":"Malignant Melanoma","enrollment":29},{"nctId":"NCT06410248","phase":"PHASE1","title":"Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2024-07-23","conditions":"Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma","enrollment":30},{"nctId":"NCT01858168","phase":"PHASE1","title":"Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2013-07-01","conditions":"Ewing Sarcoma, Rhabdomyosarcoma","enrollment":49},{"nctId":"NCT03728361","phase":"PHASE2","title":"Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dwight Owen","startDate":"2018-12-31","conditions":"Grade I Neuroendocrine Carcinoma, Grade II Neuroendocrine Carcinoma, Grade III Neuroendocrine Carcinoma","enrollment":55},{"nctId":"NCT05040360","phase":"PHASE2","title":"Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2022-05-05","conditions":"Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8","enrollment":141},{"nctId":"NCT02344355","phase":"PHASE2","title":"A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bryan Allen","startDate":"2017-03-13","conditions":"Glioblastoma Multiforme","enrollment":90},{"nctId":"NCT04339036","phase":"PHASE2","title":"CapTemY90 for Grade 2/3 NET Liver Metastases","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-10-07","conditions":"Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors","enrollment":70},{"nctId":"NCT03880019","phase":"PHASE2","title":"A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-19","conditions":"Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Uterine Corpus Leiomyosarcoma","enrollment":23},{"nctId":"NCT04900792","phase":"PHASE1","title":"A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bryan Allen","startDate":"2023-02-28","conditions":"Glioblastoma, Glioblastoma Multiforme","enrollment":17},{"nctId":"NCT07243470","phase":"PHASE1, PHASE2","title":"Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2025-11-04","conditions":"Glioma, CNS Tumor, Adult, CNS Tumor, Childhood","enrollment":70},{"nctId":"NCT05030298","phase":"PHASE1","title":"Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-05-23","conditions":"Malignant Glioma","enrollment":28},{"nctId":"NCT01139970","phase":"PHASE1","title":"Veliparib and Temozolomide in Treating Patients With Acute Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-06-04","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","enrollment":66},{"nctId":"NCT05142241","phase":"PHASE2","title":"Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-11","conditions":"Adrenal Gland Pheochromocytoma, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm","enrollment":14},{"nctId":"NCT03746080","phase":"PHASE2","title":"Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma","status":"COMPLETED","sponsor":"Lawrence D Recht","startDate":"2018-12-04","conditions":"Glioblastoma, Glioblastoma With Primitive Neuronal Component, Gliosarcoma","enrollment":21},{"nctId":"NCT05902169","phase":"PHASE3","title":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"CarThera","startDate":"2024-01-29","conditions":"Glioblastoma, Recurrent Glioblastoma, GBM","enrollment":560},{"nctId":"NCT03672773","phase":"PHASE2","title":"Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2018-10-31","conditions":"Recurrent Extensive Stage Small Cell Lung Carcinoma, Refractory Extensive Stage Small Cell Lung Carcinoma","enrollment":35},{"nctId":"NCT02977780","phase":"PHASE2","title":"INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)","status":"RECRUITING","sponsor":"Patrick Wen, MD","startDate":"2017-02-09","conditions":"Glioblastoma","enrollment":460},{"nctId":"NCT01638546","phase":"PHASE2","title":"Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-07-27","conditions":"Recurrent Lung Small Cell Carcinoma","enrollment":97},{"nctId":"NCT04555577","phase":"PHASE1","title":"Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-09-20","conditions":"Glioblastoma, Gliosarcoma","enrollment":29},{"nctId":"NCT04385277","phase":"PHASE2","title":"Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-12-31","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":41},{"nctId":"NCT04373785","phase":"PHASE1, PHASE2","title":"NG101m Adjuvant Therapy in Glioblastoma Patients","status":"NOT_YET_RECRUITING","sponsor":"NeuGATE Theranostics","startDate":"2027-01-01","conditions":"Glioblastoma Multiforme","enrollment":52},{"nctId":"NCT01991977","phase":"PHASE2","title":"18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-12","conditions":"Malignant Glioma","enrollment":91},{"nctId":"NCT05429502","phase":"PHASE1","title":"Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-12-27","conditions":"Neuroblastoma","enrollment":12},{"nctId":"NCT03426891","phase":"PHASE1","title":"Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-03-16","conditions":"Glioblastoma, Brain Tumor, GBM","enrollment":21},{"nctId":"NCT03535350","phase":"PHASE1","title":"Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2018-08-24","conditions":"Glioblastoma","enrollment":36},{"nctId":"NCT03174197","phase":"PHASE1, PHASE2","title":"Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-06-30","conditions":"Glioblastoma, Gliosarcoma","enrollment":60},{"nctId":"NCT04337177","phase":"PHASE1","title":"Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors","status":"RECRUITING","sponsor":"Valent Technologies, LLC","startDate":"2021-10-25","conditions":"Solid Tumors, Neuroblastoma, Rhabdomyosarcoma","enrollment":20},{"nctId":"NCT03970447","phase":"PHASE2, PHASE3","title":"A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma","status":"RECRUITING","sponsor":"Global Coalition for Adaptive Research","startDate":"2019-07-30","conditions":"Glioblastoma","enrollment":1280},{"nctId":"NCT01107522","phase":"PHASE1","title":"Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas","status":"UNKNOWN","sponsor":"Tactical Therapeutics, Inc.","startDate":"2010-05","conditions":"Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas","enrollment":100},{"nctId":"NCT03149575","phase":"PHASE3","title":"VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM","status":"TERMINATED","sponsor":"DelMar Pharmaceuticals, Inc.","startDate":"2017-10-27","conditions":"Glioblastoma Multiforme, Glioblastoma, Glioma","enrollment":2},{"nctId":"NCT05190315","phase":"PHASE1","title":"Chlorpromazine and Standard of Care in Glioblastoma","status":"COMPLETED","sponsor":"Mohammed Milhem","startDate":"2022-01-28","conditions":"Glioblastoma Multiforme","enrollment":10},{"nctId":"NCT02717962","phase":"PHASE2","title":"Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting","status":"COMPLETED","sponsor":"Kintara Therapeutics, Inc.","startDate":"2017-01-20","conditions":"Glioma, Glioblastoma, Glioblastoma Multiforme","enrollment":118},{"nctId":"NCT01478178","phase":"PHASE1, PHASE2","title":"Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma","status":"COMPLETED","sponsor":"Kintara Therapeutics, Inc.","startDate":"2011-10","conditions":"Glioma, Glioblastoma, Glioblastoma Multiforme","enrollment":55},{"nctId":"NCT04747145","phase":"PHASE2","title":"Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-06-03","conditions":"Glioblastoma","enrollment":38},{"nctId":"NCT06023641","phase":"PHASE2","title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-13","conditions":"Rhabdomyosarcoma","enrollment":135},{"nctId":"NCT04388475","phase":"PHASE2","title":"Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Oblato, Inc.","startDate":"2020-06-12","conditions":"Recurrent Malignant Glioma, Brain Glioblastoma","enrollment":57},{"nctId":"NCT03018288","phase":"PHASE2","title":"Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-09-21","conditions":"Glioblastoma","enrollment":90},{"nctId":"NCT03137888","phase":"PHASE2","title":"Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma","status":"COMPLETED","sponsor":"Emory University","startDate":"2017-09-20","conditions":"Glioblastoma, Gliosarcoma","enrollment":30},{"nctId":"NCT04239092","phase":"PHASE1","title":"9-ING-41 in Pediatric Patients With Refractory Malignancies.","status":"TERMINATED","sponsor":"Actuate Therapeutics Inc.","startDate":"2020-06-05","conditions":"Refractory Cancer, Refractory Neoplasm, Cancer Pediatric","enrollment":40},{"nctId":"NCT07027748","phase":"PHASE1","title":"Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma","status":"RECRUITING","sponsor":"Steven DuBois, MD","startDate":"2025-06-27","conditions":"Neuroblastoma, Neuroblastoma Recurrent, Relapsed Neuroblastoma","enrollment":18},{"nctId":"NCT03180502","phase":"PHASE2","title":"Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2018-01-23","conditions":"Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma","enrollment":120},{"nctId":"NCT03778294","phase":"PHASE2","title":"18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-03-28","conditions":"Glioblastoma, Malignant Glioma","enrollment":43},{"nctId":"NCT04047706","phase":"PHASE1","title":"Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2019-08-13","conditions":"Glioblastoma","enrollment":18},{"nctId":"NCT02781792","phase":"PHASE2","title":"Temozolomide Chronotherapy for High Grade Glioma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-08-11","conditions":"Glioma, Glioblastoma Multiforme","enrollment":42},{"nctId":"NCT05879367","phase":"PHASE1","title":"Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma","status":"RECRUITING","sponsor":"Orbus Therapeutics, Inc.","startDate":"2023-07-24","conditions":"Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme","enrollment":66},{"nctId":"NCT02667587","phase":"PHASE3","title":"An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-05-09","conditions":"Brain Neoplasms","enrollment":716},{"nctId":"NCT00629343","phase":"PHASE1","title":"Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide","status":"COMPLETED","sponsor":"Columbia University","startDate":"2007-10","conditions":"Soft Tissue Sarcoma, Mesothelioma","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":65,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_1","status":"active","brandName":"Temodal","genericName":"Temodal","companyName":"Armando Santoro, MD","companyId":"armando-santoro-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Temozolomide, also known as Temodar, is an anticancer medication used to treat various types of brain tumors, including glioblastoma, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma. It is a small molecule DNA inhibitor that can be taken by mouth or via intravenous infusion.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":5,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T09:50:23.664473+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}